Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics    SIGHT   FR0013183985

GENSIGHT BIOLOGICS

(SIGHT)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
1.78(c) 1.8(c) 2.01(c) 2.14(c) 2.17(c) Last
217 900 198 875 477 709 365 827 154 517 Volume
-6.32% +1.12% +11.67% +6.47% +1.40% Change
More quotes
Financials (EUR)
Sales 2018 3,50 M
EBIT 2018 -26,6 M
Net income 2018 -26,6 M
Finance 2018 23,2 M
Yield 2018 -
Sales 2019 3,50 M
EBIT 2019 -28,7 M
Net income 2019 -28,7 M
Debt 2019 5,10 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 8,73x
EV / Sales2019 16,8x
Capitalization 53,7 M
More Financials
Company
GenSight Biologics specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2017, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber... 
More about the company
Surperformance© ratings of GenSight Biologics
Trading Rating : Investor Rating :
More Ratings
Latest news on GENSIGHT BIOLOGICS
02/14GENSIGHT BIOLOGICS : Announces Publication of Positive Safety Data from Phase I/..
AQ
01/14GENSIGHT BIOLOGICS : Corporate presentation, January 2019
PU
2018GENSIGHT BIOLOGICS : Corporate presentation, November, 2018
PU
2018GENSIGHT BIOLOGICS : Reports its Cash Position as of September 30, 2018
PU
2018GENSIGHT BIOLOGICS : Half-year results
CO
2018GENSIGHT BIOLOGICS : Half-year report
CO
2018GENSIGHT BIOLOGICS : Key Opinion Leaders highlight GS010 efficacy and patient be..
PU
2018GENSIGHT BIOLOGICS : 1st quarter earnings
CO
2018GENSIGHT BIOLOGICS : falls after Phase III neuropathy miss
AQ
2018GENSIGHT BIOLOGICS : announces topline results from REVERSE Phase III clinical t..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Bio Therapeutic Drugs
Chart GENSIGHT BIOLOGICS
Duration : Period :
GenSight Biologics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 5,70 €
Spread / Average Target 163%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Independent Chairman
Thomas Gidoin Chief Financial Officer
Barrett Katz Chief Medical Officer
Harvey N. Masonson Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS-34.83%61
GILEAD SCIENCES6.11%87 436
VERTEX PHARMACEUTICALS12.08%48 081
REGENERON PHARMACEUTICALS9.37%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252